Selpercatinib was assessed in a phase I/II trial of patients with RET fusion+ NSCLC, some of whom had received platinum-based chemotherapy, and reported a remarkable icORR of 91% and median DOR of 10.1 months in a small cohort of 11 patients (102). The gene discussed is RET; the disease is non-small cell lung carcinoma.